A central insight from new research published in Science is that Alzheimer's is not a sudden event, but a biological process that develops over many years, often decades, before the first symptoms appear.
What is now changing the playing field is biomarkers. The blood marker p-tau217 in particular has proven to be one of the most accurate indicators we have today. It reflects the ongoing disease process in the brain and can identify changes long before clinical symptoms are noticeable.
But here is an important nuance: measuring a biomarker is not the same as understanding risk. Not everyone with elevated levels develops the disease, and the timing within the disease process matters greatly. In other words, we are further ahead in our ability to measure than in our ability to treat. That is why context is crucial.
At Executive Health we work with a combined model for brain health:
- p-tau217: biological signal
- Volumetric MRI analysis: structural changes in the brain
- Cognitive tests: functional impact
Together, this provides a considerably more complete picture than any single data point.
Instead of asking "do I have Alzheimer's?", we can begin to ask a more relevant question: what does my neurological trajectory look like, and can it be influenced?
This is where the medicine of the future is heading.
From diagnosis → to risk analysis
From reactive care → to proactive strategy
We are approaching a point where brain health can be tracked, understood and influenced long before disease arises. But it requires that we interpret biomarkers in the right context, not in isolation.
